导管切除与高级治疗对于患有严重心力衰竭和心室电风暴的患者
Andrew Y Lin1, Maedha Begur1, Emily Margolin1
1Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California.
Heart rhythm
|September 27, 2024
概括
在严重心力衰竭中,对心室高心电风暴的导管切除提供了与先进疗法相似的存活率. 然而,心脏移植率在切除后很高,具有特定的UNOS状态和早期复发预测结果.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 有限的数据存在于对比导管切除与高级疗法对于严重心力衰竭 (HF) 患者经历电风暴 (ES).
- 严重的HF被定义为射出分数≤35%或显著的心肌病.
- 心室ES在HF管理中构成了关键的挑战.
研究的目的:
- 为了比较心室动脉冲动 (VT) 切除与先进疗法 (左心室辅助装置[LVAD]或心脏移植[HT]) 在严重的ESHF中.
- 为了确定影响静脉瘤切除患者结果的因素.
主要方法:
- 在2012-2022年期间接受治疗的73名严重HF和ES患者的回顾性评估.
- 患者接受了静脉管切除或先进疗法 (HT/LVAD).
- 评估了住院不良事件和1年后的结果.
主要成果:
- 在静脉管切除 (76.7%) 和先进疗法 (86.7%) 组之间,一年的存活率是可比的 (P = .308).
- 废除组中的23.3%的患者最终接受了HT.
- 器官共享联合网络 (UNOS) 状态1或2和早期VT复发预测HT或切除后死亡.
结论:
- 在ES严重的HF中,静脉除用于静脉除显示了与前期先进治疗相似的存活率.
- 在VT切除后观察到高后续HT率.
- UNOS状态和早期VT复发是HT或切除后死亡率的关键预测因素.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.4K
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.4K
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
01:29Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
2
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
2
01:25Dysrhythmias VI: Management of Dysrhythmias
3
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
3
01:30Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
1
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1